Hydroxychloroquine: Phase I data

Data from the second dose cohort of the open-label, dose-escalation, U.S. Phase I HSO1 trial in patients with relapsed or refractory solid tumors showed that once-daily 200 mg oral hydroxychloroquine plus twice-daily Nexavar sorafenib (200 mg in the AM and 400 mg in the PM) produced no significant toxicities. VG Life Sciences said enrollment in the third dose cohort evaluating once-daily 200 mg oral hydroxychloroquine plus twice-daily 400 mg Nexavar has been initiated. The fourth and final dose cohort will evaluate once-daily 400 mg oral hydroxychloroquine plus twice-daily 400 mg Nexavar. VG Life Sciences said it will evaluate next steps for the product after completing the trial. ...